Latest Sirolimus Stories
Sirolimus, a drug currently used to help prevent transplant rejection, can improve lung function and quality of life in individuals living with the lung disease lymphangioleiomyomatosis (LAM).
Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found that the FDA-approved drug sirolimus, used primarily to prevent rejection in organ transplant patients, stabilized lung function in women with lymphangioleiomyomatosis (LAM).
HONG KONG, March 14, 2011 /PRNewswire/ -- OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent.
A study from Karolinska Institutet has shown that the body's ability to break down medicines may be closely related to exposure to sunlight, and thus may vary with the seasons.
HONG KONG, Feb.
SINGAPORE, Feb. 28, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that its novel dual mTOR/PI3 Kinase inhibitor SB2343 demonstrated excellent pharmacokinetic/pharmacodynamic (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive and resistant xenograft models.
HONG KONG, Feb.
Congenital heart diseases affect approximately one in 100 patients, making them the most common type of birth defect and the number-one cause of pediatric deaths.
DURHAM, N.C., Feb. 17, 2011 /PRNewswire/ -- Micell Technologies,(TM) Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial.
Researchers from Baylor College of Medicine have provide the first direct genetic evidence that a complex of proteins known as mammalian target of rapamycin complex 1 (mTORC1) plays a crucial role in memory formation.
- A trick or prank.